KCTD9抗体;KCTD9 Antibody—艾普蒂

+ +

•  

   

     Western blot analysis of KCTD9 expression in HepG2 cell lysate.    

  
  

The KCTD9 (Potassium Channel Tetramerization Domain Containing 9) protein belongs to the KCTD family, characterized by a conserved BTB/POZ domain that facilitates protein-protein interactions. KCTD9 is implicated in diverse cellular processes, including ubiquitination, transcriptional regulation, and cellular signaling. It may act as a substrate-specific adaptor for Cullin3-based E3 ubiquitin ligase complexes, targeting proteins for proteasomal degradation. Studies suggest roles in cancer progression, with KCTD9 potentially modulating pathways like Hippo or Wnt signaling, though its exact mechanisms remain under investigation. Dysregulation of KCTD9 has been observed in gastric, colorectal, and other cancers, correlating with tumor growth, metastasis, or therapeutic resistance, making it a biomarker candidate.

KCTD9 antibodies are essential tools for detecting endogenous KCTD9 expression and localization via techniques like Western blotting, immunohistochemistry, or immunofluorescence. They enable functional studies to explore KCTD9’s interactions (e.g., with Cullin3 or transcription factors like NF-κB), its regulatory effects on downstream targets, and its pathological relevance in cancer models. Commercially available antibodies are typically validated for specificity using knockout cell lines or siRNA knockdown. Research applications include profiling KCTD9 expression across tissues, assessing its prognostic value in oncology, and dissecting its role in ubiquitination-dependent pathways. However, antibody performance may vary depending on epitope regions (e.g., N-terminal vs. C-terminal) and post-translational modifications.